Close
Close

Marathon Pharmaceuticals, LLC. - Duchenne muscular dystrophy

Partner

Parexel International, LLC; Dohmen Life Science Services

Rare Disease

Duchenne muscular dystrophy

Sponsor

Marathon Pharmaceuticals, LLC.

Access Program Information

The expanded access program will provide access to treatment with Deflazacort in children, adolescent, and adult patients with DMD (Duchenne Muscular Dystrophy)  in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.

Contact
Locations
  • Belgium
  • Bosnia And Herzegowina
  • Bulgaria
  • Czech Republic
  • Denmark
  • Finland
  • France
  • France, Metropolitan
  • Germany
  • Gibraltar
  • Greece
  • Greenland
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malta
  • Monaco
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Free Newsletter